Abstract -We have been extensively involved in the synthesis of isoelectronic and isostructural boron analogues of the a-amino acids. These have ranged from simple glycine analogues such as H3NBH2COOH and Me2NHBH2COOH to alanine analogues. A diverse variety of analogues, including precursors and derivatives (such as peptides) have expressed potent pharmacological activity, including anticancer, antiinflanunatory, analgesic, and hypolipidemic activity in animal model studies and in virro cell cultures.
INTRODUCTION
We have been extensively involved in the synthesis and pharmacological properties of boron analogues of biologically important molecules. Many of these are isoelectronic and isostructural with their naturally occurring carbon counterparts. Based upon four-coordinate boron, they generally possess sufficient hydrolytic and oxidative stability to be used in biological studies. These may be of use to probe fundamental biochemical events at the molecular level as well as in providing entirely new classes of compounds of potential medicinal value. They may also prove valuable in Boron Neutron Capture Therapy.
AMINO ACIDS ANALOGUES
The amino acid analogues (ref. 1) have ranged from simple glycine and N-methyl substituted glycines such as H3NBH2CaH and Me3NBH2Cw to analogues of more complex amino acids such as alanine (amide), H3NB(Me)HC(O)NEtH (ref.
2). The latter has been prepared from Me3NBH2CaH in a multistep process as outlined below. In addition to amino acid analogues, we have synthesized analogues of other biomolecules such as choline and thiocholine derivatives, and analogues of potent therapeutic agents such as phosphonoacetate. Recently we have embarked on a new area of boronated nucleic acids which is described below.
BORONATED NUCLEOSIDES AND NUCLEOTIDES
The synthesis of new classes of nucleic acid components has been stimulated by antiviral and antitumor activity associated with a wide variety of structurally divergent modified nucleic acids. In addition to therapeutic potential, modified nucleosides, mononucleotides and oligonucleotides may be useful as diagnostic agents and as probes for studying fundamental biological processes at the molecular level. For example, modified nucleoside mono-, di-, or triphosphates can act as substrates for various enzymes and interfere with their natural function. Modified oligonucleotides,"antisense" agents, may be used to specifically block gene expression and therefore may be useful as inhibitors of viral growth as well as other unwanted gene expression (ref .5) e.g. expression of oncogenes.
Of considerable added importance is the potential for boronated nucleic acids to localize in the nucleus and prove very effective in boron neuwn capture therapy of cancer. Specifically designed boronated oligonucleotides may also function as antisense molecules and inhibit or completely block expression of oncogenes.
In order to be useful as antisense inhibitors, the nucleic acid analogs should possess the following properties (ref. 
S) and phosphoramidates (-PNR2
). These analogs have been shown to inhibit various viruses e.g. HIV, Herpes Simplex viruses , etc., and expression of oncogenes. Many homo sequences of modified oligomers are also very effective in inhibiting viral growth indicating that in addition to the antisense mechanism, other mechanisms may also be operational. Boron containing oligonucleotides may also exhibit inhibitory effects by one or more of these mechanisms.
We have recently synthesized two new classes of nucleic acids which have been modified to contain boron.
Class I nucleosides with boronanation of the base
Class 1 is comprised of nucleosides which have been modified on the base to form cyanoborane adducts, -1. These modified nucleosides were prepared by the reaction of 3',5'-O-triisopropylsilyl-2-deoxynucleosides The boranophosphate species is very closely related to the normal oxygen oligonucleotides (0-oligos, Fig. 2a ) and the oligonucleotide methylphosphonates (Fig. 2c) .
The borane (BH3) group is isoelectronic with oxygen and the boranophosphate intemucleotide group is negatively charged like the normal O-oligos. The borane group is also isoelectronic, as well as isostructural, with the oligonucleotide methylphosphonates which are nuclease resistant. Thus, the boranophosphate oligo may represent an important and perhaps ideal "antisense" species in that the nucleotide bases are unaltered (and thus should maintain binding specificity) while the backbone remains negatively charged (and thus should be water soluble) like the O-oligo. Since BH3 is much more hydrophobic than oxygen, it may impart a greater membrane penneability than the 0-oligo, yet maintain nuclease resistance like the methylphosphonates. Although compounds containing boron-hydride bonds are susceptible to hydrolysis, the B-H bond in boranophosphates possesses unusual hydrolytic stability, as described below. Similarly, in acid the dimer is fairly stable. In 1N HC1:MeOH (l:l), ~1 0 % of the boranophosphate group was hydrolyzed to normal phosphate. In addition, it removed the 3'-acetate p u p . Since, these conditions were very drastic, we expect that under in vivo conditions or solid phase synthesis conditions, the boranophosphate group should be stable.
The boranophosphate group is also very resistant to cleavage by exonucleases. (Snake venom and calf spleen phosphodiesterases). Thus, under conditions where normal TpT dimer is > 95% cleaved, the boronated dimer 2 is >92% intact.
Further. we have also synthesized a trinucleotide, by repeating the steps 1 and 2 shown in s. Synthesis of the trimer indicates that the boranophosphate backbone is compatible with reagents needed for chain elongation. The work described so far involves only thymidine. Synthesis of boronated oligonucleotides with other bases is in progress.
Potent biological activity has been found for these new species. The cytotoxicity of a number of boronated nucleosides and nucleotides in murine and human tumor cell lines has been determined. Significant activity has been observed. For example, in the human colorectal adenminoma test, compound 2 in Scheme 2 gave a p g / d E D 9 value of 0.875 compared to the standard commercial drug, 5-Fluorouracil of 3.09.
Antiinflammatory and hypolipidemic activity have also been expressed. For example, dC*BHzCN, shows a 52% inhibition of inflammation (in mice) at a dose of 8 mg/kg/day compared to the standard phenylbutazone at 47%. In cholesterol inhibition in mice, dG.BH2CN shows a lowering of serum cholesterol by 44% at a dose of 8 mg/kg/day after 16 days whereas the commercial drug clofibrate lowers serum cholesterol by 13% at a dose of 130 mg/kg/day.
These compounds are undergoing study for use in boron neutron capture therapy. In a preliminary in vivo experiment (mouse, Ehrlich Ascites Carcinoma) with the radiolabeled "4CI 2'-deoxycytidine-3N-cyanoborane, after 2 hrs, a tumor/blood ratio of 4.2 was observed and after 4 hrs, 8.5. Further testing of these species both in vitro and in vivo are underway. 
